Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression
about
Gene therapy for carcinoma of the breast: Genetic immunotherapyStructure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptideThe gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 miceTransgenic expression of P1A induced thymic tumor: a role for onco-fetal antigens in tumorigenesis.Structure of the gene of tum- transplantation antigen P35B: presence of a point mutation in the antigenic alleleCytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.AAV2-mediated in vivo immune gene therapy of solid tumours.Trial Watch: Peptide-based anticancer vaccines.Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.IFNγ producing CD8(+) T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomasImmunosuppressive tumor microenvironment in cervical cancer patientsExpression of tumour-specific antigens underlies cancer immunoeditingConsensus nomenclature for CD8(+) T cell phenotypes in cancerCytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopesMalignant growth in the normal host after variant selection in vitro with cytolytic T-cell linesIdentification of a unique tumor antigen as rejection antigen by molecular cloning and gene transferTumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells.Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens.Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.Decreased tumor surveillance in perforin-deficient mice.Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens.Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responsesIL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent mannerTum- antigens, TSTA, and T cell immune surveillance.Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers.Prospects for the treatment of B cell tumors using idiotypic vaccination.Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca2+ signalling and granule mobilization.Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-tumor immunotherapy.Targeting neoantigens to augment antitumour immunity.Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs.Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytesIFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells.Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.Genes coding for tumor antigens recognized by cytolytic T lymphocytes.
P2860
Q24797848-C649D8C7-814F-4B0B-A045-4410DF17728EQ33255829-4C7A61FD-3DD6-4FC8-8316-273182D25045Q33387226-C5C2FE55-BEF5-4CC4-A4DB-907F37067E53Q33728430-35F5D576-BA69-48C6-8D17-34BE520A25C3Q33751018-B9BF1190-2BB1-46A7-99EB-C09570530536Q33850807-7983B28A-A6C0-4724-A02A-B15325C02EC6Q34468330-46932101-DA7A-4614-8DB7-E405A2389916Q34483345-43AE792F-A3CF-4A66-9775-120C2F3B6D6CQ34755544-96E340A1-1B08-4B72-980A-DFB54602B0B3Q35507485-7F2D6D22-2EBF-4A1E-9FF4-1455A27D4FBFQ35603131-43FA35BC-6C8A-4444-8DFC-7C139814E6A5Q35785378-7D5917C5-E330-43A4-B06A-99D25361A5C2Q35798822-19F28765-F11F-4693-8188-CBB91C55DA36Q36231676-7B48D2BC-B97A-462A-AB06-D2438CC6B7FBQ36267070-AE04005D-205A-43DD-804D-3A4D0B17D1D1Q36353080-6A057FF4-BA39-4610-8417-D28CA47F9359Q36356571-9315568E-B6DA-4394-B437-E4078CB62D38Q36356745-6BF04761-0802-42C0-9975-E7C8AE681E40Q36362788-68A96404-D095-4AE5-A977-F3FBE5D00F8FQ36366282-64054108-988A-4AF9-8D48-2E94ACB5A8D8Q36367528-43B9FFFE-1FF9-4FDF-BBF9-F6BDAD426F6CQ36367821-B0EB4C97-ADE7-42C8-B26B-F67608A42429Q36369462-41B9C801-3A77-4F88-901F-96A1EBD1ACABQ36402716-40406203-4737-46E7-B8FA-65E06C4D0330Q36831746-A0D54724-CD88-4583-B281-F71A7430CB9AQ36855263-E139B177-3421-422C-8FEC-071FC48A4501Q36968849-F2C78A98-0E2E-46A8-AADE-57A227735A56Q37519025-8AC349C9-AD32-49EE-8D12-88EB739DF357Q38101679-55B24B3A-57DC-466C-8B5C-C3A3C823904BQ38209942-B78F5D8A-2C0B-4969-890F-FD8D120CA28CQ38246920-F292C607-0616-46BE-8B2C-420C2D2DB227Q38734283-55446D1F-5FED-4D2A-A26A-5C357A3880EDQ39117175-1B68F658-9AAE-4E51-834E-E21D0C7EAE4BQ39149196-4FC019A1-52AD-43B8-B6E3-50DCC1056003Q39713047-E1E938BD-2A04-46AF-814E-E4E42D3F2927Q39752699-2535EAA1-B2E5-4216-BB54-4EED3C583CA0Q40006095-7013FD3B-5542-4EDF-9D8C-CB86F53967DFQ40309584-C39568E5-01FB-4B06-81FA-CB7BCF7C6100Q40327982-1553DC46-81B9-4C0F-926B-7D527877CB21Q40433302-02CB4060-F229-493D-AD10-E4E6611D7ED3
P2860
Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh
1983年學術文章
@zh-hant
name
Escape of mouse mastocytoma P8 ...... rather than immunosuppression
@ast
Escape of mouse mastocytoma P8 ...... rather than immunosuppression
@en
type
label
Escape of mouse mastocytoma P8 ...... rather than immunosuppression
@ast
Escape of mouse mastocytoma P8 ...... rather than immunosuppression
@en
prefLabel
Escape of mouse mastocytoma P8 ...... rather than immunosuppression
@ast
Escape of mouse mastocytoma P8 ...... rather than immunosuppression
@en
P2093
P2860
P356
P1476
Escape of mouse mastocytoma P8 ...... rather than immunosuppression
@en
P2093
P2860
P304
P356
10.1084/JEM.157.3.1040
P407
P577
1983-03-01T00:00:00Z